Hong Kong Prostate Cancer Study Group Database
Launched by CHINESE UNIVERSITY OF HONG KONG · Nov 15, 2017
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The Hong Kong Prostate Cancer Study Group is conducting a study to create a local registry for prostate cancer. This registry aims to collect important information about how prostate cancer is diagnosed and treated in Hong Kong. By gathering data on patients' experiences and outcomes, the study hopes to improve our understanding of prostate cancer, which is becoming increasingly common among men in the region. The information gathered will be useful for research, educating the public, and planning healthcare services.
To participate in this study, you need to be a man aged 18 or older who has been clinically diagnosed with prostate cancer. However, if you have a specific type of prostate cancer called ductal type, you won’t be eligible. If you join, you can expect to contribute valuable information that may help improve treatment and care for future patients. This study is currently looking for participants, and your involvement could make a difference in how prostate cancer is managed in the community.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patient at the age of 18 or above
- • Patients with clinical diagnosis of prostate cancer
- Exclusion Criteria:
- • Patients diagnosed to have ductal type of prostate cancer
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, , Hong Kong
Patients applied
Trial Officials
Chi Fai NG, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials